Human Vaccines & Immunotherapeutics (Jul 2021)

Meningococcal vaccines in China

  • Yinghua Xu,
  • Yanan Li,
  • Shanshan Wang,
  • Maoguang Li,
  • Miao Xu,
  • Qiang Ye

DOI
https://doi.org/10.1080/21645515.2020.1857201
Journal volume & issue
Vol. 17, no. 7
pp. 2197 – 2204

Abstract

Read online

Meningococcal meningitis caused by Neisseria meningitidis is a reportable infectious disease in China, due to the high incidence of meningitis in the era before the availability of vaccines. The disease incidence was markedly reduced after meningococcal vaccination was introduced in the 1980s. Currently, there are polysaccharide, conjugate, and combined vaccine formulations against meningococcal meningitis in the Chinese market, almost all of which are produced by domestic manufacturers. It is necessary to further enhance national meningococcal surveillance to improve the level of prevention and control of meningococcus. However, the immune efficacy and persistence of immunity of vaccines should be monitored. More importantly, additional investments should be made to develop serogroup B meningococcal vaccines.

Keywords